[go: up one dir, main page]

PL1926813T3 - Populacje komórkowe mające aktywność immunoregulatorową, sposób izolacji i zastosowania - Google Patents

Populacje komórkowe mające aktywność immunoregulatorową, sposób izolacji i zastosowania

Info

Publication number
PL1926813T3
PL1926813T3 PL06777197T PL06777197T PL1926813T3 PL 1926813 T3 PL1926813 T3 PL 1926813T3 PL 06777197 T PL06777197 T PL 06777197T PL 06777197 T PL06777197 T PL 06777197T PL 1926813 T3 PL1926813 T3 PL 1926813T3
Authority
PL
Poland
Prior art keywords
applications
cell populations
isolation method
immunoregulatory activity
immunoregulatory
Prior art date
Application number
PL06777197T
Other languages
English (en)
Other versions
PL1926813T5 (pl
Inventor
Dirk Büscher
De La Peña Manuel Ángel González
Mora Mario Delgado
Original Assignee
Tigenix, S.A.U.
Consejo Superior De Investigaciones Cientificas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1926813(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tigenix, S.A.U., Consejo Superior De Investigaciones Cientificas filed Critical Tigenix, S.A.U.
Publication of PL1926813T3 publication Critical patent/PL1926813T3/pl
Publication of PL1926813T5 publication Critical patent/PL1926813T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL06777197T 2005-09-23 2006-09-22 Populacje komórkowe mające aktywność immunoregulatorową, sposób izolacji i zastosowania PL1926813T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05077186 2005-09-23
PCT/EP2006/009244 WO2007039150A2 (en) 2005-09-23 2006-09-22 Cell populations having immunoregulatory activity, method for isolation and uses
EP06777197.2A EP1926813B2 (en) 2005-09-23 2006-09-22 Cell populations having immunoregulatory activity, method for isolation and uses

Publications (2)

Publication Number Publication Date
PL1926813T3 true PL1926813T3 (pl) 2017-01-31
PL1926813T5 PL1926813T5 (pl) 2019-11-29

Family

ID=37708240

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06777197T PL1926813T5 (pl) 2005-09-23 2006-09-22 Populacje komórkowe mające aktywność immunoregulatorową, sposób izolacji i zastosowania

Country Status (19)

Country Link
US (5) US20090130067A1 (pl)
EP (4) EP3184631B1 (pl)
JP (2) JP5925408B2 (pl)
KR (2) KR101536239B1 (pl)
CN (2) CN107723274B (pl)
AU (1) AU2006299144A1 (pl)
CA (2) CA2953782C (pl)
CY (1) CY1117972T1 (pl)
DK (1) DK1926813T4 (pl)
ES (2) ES2751692T3 (pl)
HU (1) HUE030503T2 (pl)
IL (3) IL190363A0 (pl)
LT (1) LT1926813T (pl)
MX (1) MX342474B (pl)
PL (1) PL1926813T5 (pl)
PT (1) PT1926813T (pl)
SG (3) SG10201400793RA (pl)
SI (1) SI1926813T2 (pl)
WO (1) WO2007039150A2 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
EP3184631B1 (en) 2005-09-23 2020-08-12 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
ATE534415T1 (de) 2005-12-13 2011-12-15 Harvard College Gerüste zur zelltransplantation
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
WO2009102465A2 (en) 2008-02-13 2009-08-20 President And Fellows Of Harvard College Continuous cell programming devices
SG191701A1 (en) 2008-03-28 2013-07-31 Stemcyte Inc Treatment of brain damage using umbilical cord blood cells
PT3320912T (pt) * 2008-04-17 2021-05-24 Io Biotech Aps Imunoterapia à base de indoleamina 2,3-dioxigenase
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
AU2009201915C1 (en) 2008-08-22 2015-02-26 Regeneus Ltd Therapeutic methods
EP2204442A1 (en) * 2008-10-01 2010-07-07 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method of enriching stem cells in culture
GB0820397D0 (en) 2008-11-07 2008-12-17 Cellerix Sa Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
JP5892931B2 (ja) 2009-07-09 2016-03-23 タイジェニックス，エス．アー． 細胞治療において使用するための方法および組成物
CA2768552A1 (en) 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
CA2772204A1 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
GB0918615D0 (en) 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
PT2624873T (pt) 2010-10-06 2020-03-04 Harvard College Hidrogéis injectáveis formadores de poros para terapias celulares à base de materiais
US20140154274A1 (en) 2011-01-12 2014-06-05 Tigenix Nv Methods and compositions for use in intralymphatic cellular therapies
WO2012123401A1 (en) * 2011-03-11 2012-09-20 Tigenix, S.A. Cell populations having immunoregulatory activity, method for isolation and uses
CN103619177A (zh) * 2011-04-25 2014-03-05 南加州大学 通过抑制干扰素-γ和肿瘤坏死因子-α来改善组织再生的方法和组合物
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
JP2014515258A (ja) 2011-05-19 2014-06-30 ティゲニックス エス．エー．ユー 免疫調節活性を有する細胞集団、その調製方法、及び、その使用
CA2870309C (en) 2012-04-16 2024-02-20 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
JP6412933B2 (ja) * 2013-06-25 2018-10-24 ティジェニクス エス．エー．ユー． 免疫調節活性を有する細胞集団、その調製方法および使用
EP3027235A1 (en) 2013-07-30 2016-06-08 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
CA2944492A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
SG11201610844PA (en) 2014-06-30 2017-01-27 Tigenix S A U Mesenchymal stromal cells for treating sepsis
US20170136065A1 (en) 2014-06-30 2017-05-18 Tigenix S.A.U. Mesenchymal stromal cells for treating rheumatoid arthritis
JP2016017068A (ja) * 2014-07-10 2016-02-01 国立大学法人金沢大学 脂肪組織由来間質細胞群を含む消化管炎症治療剤
KR101675521B1 (ko) * 2014-07-11 2016-11-17 대한민국 인돌아민 2,3-디옥시게나아제를 이용하여 인터페론-감마의 발현을 조절하는 방법
CA3012602A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
EP3280464A4 (en) 2015-04-10 2018-09-26 President and Fellows of Harvard College Immune cell trapping devices and methods for making and using the same
CA2986702C (en) 2015-05-21 2023-04-04 David Wang Modified demineralized cortical bone fibers
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
JP7138864B2 (ja) 2016-02-06 2022-09-20 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫を再構成するための造血ニッチの再現
WO2017144552A1 (en) 2016-02-22 2017-08-31 Centauri Biotech. S.L. Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso)
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
MA45738A (fr) 2016-07-13 2019-05-22 Harvard College Échafaudages mimétiques de cellules présentant l'antigène et procédés pour les préparer et les utiliser
JP2020511464A (ja) 2017-03-15 2020-04-16 オルカ バイオシステムズ インコーポレイテッド 造血幹細胞移植用の組成物および方法
WO2019174842A1 (en) 2018-03-13 2019-09-19 Oxacell Ag Cell products with improved stability and uses thereof
EP3875097B1 (en) 2018-06-15 2023-06-07 NextPhase Therapeutics, Inc. Pharmaceutical composition for dermatology and uses thereof
AU2019447274A1 (en) * 2019-05-21 2021-12-09 Emo Biomedicine Corp. Use of mesenchymal stem cells in treating immune-related diseases
KR102438419B1 (ko) * 2021-12-01 2022-09-01 메디포스트(주) Cd47 과발현 중간엽 줄기세포를 포함하는 폐 질환 예방 또는 치료용 조성물

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145770A (en) 1990-06-04 1992-09-08 Biosurface Technology, Inc. Cryopreservation of cultured epithelial sheets
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6010696A (en) 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
WO1995033421A1 (en) 1994-06-06 1995-12-14 Case Western Reserve University Biomatrix for tissue regeneration
US6174333B1 (en) 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
WO1999028444A1 (en) 1997-12-02 1999-06-10 Zen Bio, Inc. Differentiation of adipose stromal cells into osteoblasts and uses thereof
WO1999029852A1 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
ATE265220T1 (de) 1998-02-04 2004-05-15 Gen Hospital Corp Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US9585916B2 (en) 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
JP2002510655A (ja) * 1998-04-03 2002-04-09 オシリス セラピューティクス，インコーポレイテッド 免疫抑制剤としての間葉幹細胞によるｔ細胞応答を阻害する方法とその利用
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
EP1165830B1 (en) 1999-03-10 2017-07-12 University of Pittsburgh of the Commonwealth System of Higher Education Adipose-derived stem cells and lattices
US20050153442A1 (en) 1999-03-10 2005-07-14 Adam Katz Adipose-derived stem cells and lattices
US20030082152A1 (en) 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
US7670628B2 (en) 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
US7078232B2 (en) 1999-08-19 2006-07-18 Artecel, Inc. Adipose tissue-derived adult stem or stromal cells for the repair of articular cartilage fractures and uses thereof
US20010046489A1 (en) 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
JP4680483B2 (ja) 2001-02-23 2011-05-11 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組織および臓器の治療および修復に用いるための幹細胞マトリックスの迅速な調製方法
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
HUP0500477A3 (en) * 2001-11-09 2010-01-28 Artecel Sciences Methods and compositions for the use of stromal cells to support embryonic and adult stem cells
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
AU2002347182A1 (en) * 2001-12-18 2003-06-30 Mondobiotech Licensing Out Ag Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
EP1499347A2 (en) 2002-03-15 2005-01-26 Department of Veterans Affairs, Rehabilitation R&D Service Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
AU2003239016B2 (en) 2002-06-14 2007-09-20 Xintela Ab Marker for stem cells and its use
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20040101959A1 (en) 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells
CA2521217C (en) 2003-04-01 2013-05-14 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
US7494812B2 (en) * 2003-04-01 2009-02-24 University Of Southern California Generation of human regulatory T cells by bacterial toxins for the treatment of inflammatory disorders
ES2265199B1 (es) * 2003-06-12 2008-02-01 Cellerix, S.L. Celulas madre adultas multipotentes procedentes de condrocitos desdiferenciados y sus aplicaciones.
CA2530416C (en) 2003-06-27 2015-08-25 Ethicon, Incorporated Postpartum cells derived from placental tissue, and methods of making and using the same
WO2005035738A1 (en) 2003-10-07 2005-04-21 Biomaster Inc. Cell differentiation of adipose-derived precursor cells
ATE493492T1 (de) 2003-11-04 2011-01-15 Biomaster Inc Verfahren und system zur herstellung von stammzellen aus fettgewebe
US7968126B2 (en) 2003-12-24 2011-06-28 The Trustees Of Columbia University In The City Of New York Creation of a biological atrioventricular bypass to compensate for atrioventricular block
JP2007538000A (ja) * 2004-01-08 2007-12-27 リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 制御性ｔ細胞は自己免疫を抑制する
EP2298861B1 (en) 2004-03-22 2017-09-13 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
RU2252252C1 (ru) 2004-04-09 2005-05-20 Тепляшин Александр Сергеевич Способ выделения мезенхимальных стволовых клеток
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
ES2264862B8 (es) 2004-08-25 2017-01-20 Cellerix, S.L. Biomaterial para sutura.
ES2313805B1 (es) 2004-10-04 2009-12-23 Cellerix, S.L. Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral.
WO2006029347A2 (en) 2004-09-03 2006-03-16 University Of Maryland, Baltimore Integrin cd18 is a novel stromal stem cell marker and functions to promote osteogenesis
US20060286089A1 (en) 2005-04-08 2006-12-21 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
EP3184631B1 (en) 2005-09-23 2020-08-12 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
US20120269774A1 (en) 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
WO2009031606A1 (ja) 2007-09-07 2009-03-12 Jcr Pharmaceuticals Co., Ltd. 関節炎治療及び予防剤
EP2591789B2 (en) 2007-09-19 2022-07-20 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
WO2009050282A1 (en) 2007-10-17 2009-04-23 Txcell Tr1 cells, mesenchymal stem cells and uses thereof
GB0814249D0 (en) 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
ES2345867B1 (es) 2009-04-03 2011-07-28 Fundacion Instituto Mediterraneo Para La Biotecnologia Y La Investigacion Sanitaria (Imabis) Celulas madre multipotentes derivadas de estroma de mesenterio.
JP5892931B2 (ja) 2009-07-09 2016-03-23 タイジェニックス，エス．アー． 細胞治療において使用するための方法および組成物
US20140154274A1 (en) 2011-01-12 2014-06-05 Tigenix Nv Methods and compositions for use in intralymphatic cellular therapies
WO2012123401A1 (en) 2011-03-11 2012-09-20 Tigenix, S.A. Cell populations having immunoregulatory activity, method for isolation and uses
US20140134140A1 (en) 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections
CA3188652A1 (en) 2013-03-15 2014-09-18 Tigenix, S.A.U Lymphocyte biomarkers for determining the clinical response to cell therapy
JP6412933B2 (ja) 2013-06-25 2018-10-24 ティジェニクス エス．エー．ユー． 免疫調節活性を有する細胞集団、その調製方法および使用

Also Published As

Publication number Publication date
IL228670A0 (en) 2013-12-31
CY1117972T1 (el) 2017-05-17
CA2953782A1 (en) 2007-04-12
SG165418A1 (en) 2010-10-28
JP5925408B2 (ja) 2016-05-25
CA2953782C (en) 2023-09-12
SG10201400793RA (en) 2014-08-28
CA2623353C (en) 2017-02-21
ES2589311T5 (es) 2020-02-14
US20220313742A1 (en) 2022-10-06
ES2589311T3 (es) 2016-11-11
SI1926813T2 (sl) 2019-11-29
IL246494B (en) 2021-09-30
IL246494A0 (en) 2016-08-31
LT1926813T (lt) 2016-11-10
EP1926813A2 (en) 2008-06-04
US20170296592A1 (en) 2017-10-19
PT1926813T (pt) 2016-09-06
EP3184631B1 (en) 2020-08-12
DK1926813T4 (da) 2019-08-19
EP1926813B1 (en) 2016-06-08
CN101313062A (zh) 2008-11-26
PL1926813T5 (pl) 2019-11-29
CA2623353A1 (en) 2007-04-12
EP3184631A1 (en) 2017-06-28
EP2340847A3 (en) 2016-11-09
HUE030503T2 (en) 2017-05-29
KR20140003631A (ko) 2014-01-09
KR20080048555A (ko) 2008-06-02
US20090130067A1 (en) 2009-05-21
SI1926813T1 (sl) 2016-10-28
EP1926813B2 (en) 2019-05-22
EP3184630B1 (en) 2019-07-17
ES2751692T3 (es) 2020-04-01
CN107723274B (zh) 2021-05-07
US12186344B2 (en) 2025-01-07
WO2007039150A2 (en) 2007-04-12
JP2014221045A (ja) 2014-11-27
SG10202001007TA (en) 2020-03-30
DK1926813T3 (en) 2016-09-19
US20170296593A1 (en) 2017-10-19
EP3184630A1 (en) 2017-06-28
JP2009508507A (ja) 2009-03-05
IL228670A (en) 2017-06-29
US9943550B2 (en) 2018-04-17
WO2007039150A3 (en) 2007-08-23
MX342474B (es) 2016-09-30
JP6089004B2 (ja) 2017-03-01
AU2006299144A1 (en) 2007-04-12
KR101536239B1 (ko) 2015-07-13
CN107723274A (zh) 2018-02-23
IL190363A0 (en) 2011-08-01
US20150224146A1 (en) 2015-08-13
EP2340847A2 (en) 2011-07-06

Similar Documents

Publication Publication Date Title
PL1926813T3 (pl) Populacje komórkowe mające aktywność immunoregulatorową, sposób izolacji i zastosowania
HK1207883A1 (en) Cell culture method and utilization of the same
EP1996931A4 (en) METHODS AND SYSTEMS FOR SORTING BLOOD GLOBULES
EP1882736A4 (en) CELL CULTURE CONTAINER
EP1938499A4 (en) CONTROLS, OBSERVERS AND APPLICATIONS THEREOF
DK1629575T3 (da) In-line-højenergi-fiber-chirp-impulsforstærkningssystem
EP1852924A4 (en) BATTERY PACK
DE602006019236D1 (de) Stromversorgungssystem
PL2634242T3 (pl) Ulepszony sposób hodowli komórek
DK1828065T3 (da) Fremgangsmåde til øget fremstilling af biogas i termofile, anaerobe fermentorer
DE50313510D1 (de) Zellkultureinsatz
DE112005001826T5 (de) Randgeschützte katalysatorbeschichtete Membranelektrodenanordnungen
DE602004022088D1 (de) Zellkultivierungskolben
FI20045162A0 (fi) Ryhmäviestintä viestinjärjestelmässä
FI20055398A0 (fi) Menetelmä solupopulaatioiden evaluoimiseksi
GB0918615D0 (en) Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
DE602006017461D1 (de) Brennstoffzellenstapel und Brennstoffzellensystem
EP1766389A4 (en) METHOD OF ISOLATING CELLS
EP1907533A4 (en) PROGENITOR CELLS AND USES THEREOF
ZA200708453B (en) Telecommunications modules, assemblies thereof and methods of using same
GB0817571D0 (en) Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
GB0904471D0 (en) Cell population having immunoregulatory activity, methods for the preparation and uses thereof
ATE443929T1 (de) Enzymatische brennstoffzelle
SE0502892L (sv) System and station
ITPD20050058U1 (it) Espositore particolarmente per stoviglie come piatti fondi, piatti piani e simili